Clostridia as live biotherapeutics: can modified
Clostridium
species enhance disease treatments?
Future Microbiol
.
2023 May:18:385-388.
doi: 10.2217/fmb-2022-0220.
Epub 2023 May 23.
Authors
Alekandra M Kubiak
1
2
,
Jella van de Laak
1
,
Yanchao Zhang
1
,
Tom S Bailey
1
,
Luuk Claessen
1
,
Philip Hittmeyer
1
,
Carlijn Vlaswinkel
1
,
Alexsandra Mowday
3
,
Ludwig J Dubois
1
,
Jan Theys
1
Affiliations
1
Department of Precision Medicine, The M-Lab, GROW - School of Oncology, Maastricht University, Maastricht, 6200, MD, The Netherlands.
2
Exomnis Biotech BV, Maastricht, 6229, EV, The Netherlands.
3
Auckland Cancer Society Research Centre, University of Auckland, Auckland, 1023, New Zealand.
PMID:
37218518
DOI:
10.2217/fmb-2022-0220
No abstract available
Keywords:
Clostridium; biotherapeutics; engineering; prevention; treatment.
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Bacteria, Anaerobic*
Clostridium*
Grants and funding
Alpe d'HuZes 13058 and 8025/Dutch Cancer society KWF